Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3H2101
Mon, 09.12.2024
aap Implantate AG
aap Implantate AG ("aap" or "Company") informs about the invitation to the Annual General Meeting published today, which will take place on January 15, 2025 in presence at the Company's headquarters in Berlin.
In particular, the Management Board and Supervisory Board will present the annual financial statements, which have now been adopted, the ap [ … ]
Tue, 03.12.2024
aap Implantate AG
The Management Board of aap Implantate AG (the "Company") today resolved to convene a General Meeting to resolve on the proposal of the Supervisory Board on the appointment of a new auditor for the financial year 2024. The background to the Supervisory Board's proposal is that the auditor elected by the Annual General Meeting on August 15, 2024 for [ … ]
Mon, 18.11.2024
aap Implantate AG
The Management Board of aap Implantate AG ("Company") informs today about the increase of the guidance of the EBITDA target. The Company increases its EBITDA in the first nine months from EUR - 1.6 million to EUR 0. Despite the ongoing investments in silver technology, which amounts to around EUR 0.6 million net after deduction of the funding supp [ … ]
Wed, 06.11.2024
aap Implantate AG
aap Implantate AG ("aap" or "Company") informs that as of October 31, 2024, conversion rights in the amount of 97.4% of the mandatory convertible bond issued in October 2023 were exercised in the context of elective conversions. This means that only 2.6% of the conversion rights have not yet been exercised, which corresponds to an amount of around [ … ]
Tue, 22.10.2024
aap Implantate AG
The Management Board of aap Implantate AG ("Company") today resolved, with the approval of the Supervisory Board, to increase the Company's share capital from currently EUR 10,979,625.00 by EUR 1,097,962.00 to EUR 12,077,587.00 by issuing 1,097.962 new no-par value bearer shares, each with a pro rata amount of the share capital of EUR 1.00 ("New Sh [ … ]
Fri, 18.10.2024
aap Implantate AG
aap Implantate AG (the “Company”) announces with reference to the ad hoc release published on October 15, 2024 at 11:25 p.m. regarding a possible cyberattack that the company's IT systems are being restarted step by step. Production was resumed after a short interruption and was almost unaffected. The ad hoc announcement on October 15, 2024 was dir [ … ]
Tue, 15.10.2024
aap Implantate AG
aap Implantate AG (the “Company”) determined that there may have been a cyber attack on the Company's IT systems. In response, the Company proactively disconnected the systems from the internet to prevent data breaches and data corruption. The IT systems and the extent of the impact are currently being reviewed. In doing so, the utmost care is bein [ … ]
Tue, 15.10.2024
aap Implantate AG
aap Implantate AG (the “Company”) determined that there may have been a cyber attack on the Company's IT systems. In response, the Company proactively disconnected the systems from the internet to prevent data breaches and data corruption. The IT systems and the extent of the impact are currently being reviewed. In doing so, the utmost care is bein [ … ]
Mon, 07.10.2024
aap Implantate AG
aap Implantate AG ("aap" or "Company") has reached another important milestone in the transition from MDD (Medical Device Directive 93/42/EEC) to MDR (Medical Device Regulation EU 2017/745). In the week from 9 September 2024 to 13 September 2024, the Notified Body mdc medical device certification GmbH audited aap's quality system according to MDR. [ … ]
Tue, 24.09.2024
aap Implantate AG
BfArM and lead ethics committee approve early end of recruitment
Last patient included on 6 August 2024;
A total of 202 patients were included in the study;
Start of the MDR registration phase
aap Implantate AG ("aap" or "Company") informs that due to the ongoing good results the patient recruitment of the human clinical trial could be terminate [ … ]